STOCK TITAN
  1. Home
  2. Sec-filings
  3. BPTSY
  4. [6-K] Biophytis SA Current Report (Foreign Issuer)

Biophytis delays 2025 annual financial statements

Biophytis SA, a clinical-stage biotechnology company, has postponed publication of its annual financial statements for the year ended December 31, 2025.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Biophytis SA, a clinical-stage biotechnology company, has postponed publication of its annual financial statements for the year ended December 31, 2025. The company says work on a €2.015 million refinancing transaction required significant management and staff attention, delaying completion of its closing process and auditor review.

As a result, Biophytis will miss the statutory April 30, 2026 deadline for publishing its 2025 accounts, but indicates it is working to finalize and release the financial statements by the end of May 2026.

Positive

  • None.

Negative

  • Delay in 2025 financial statements: Biophytis confirms it cannot meet the April 30, 2026 legal deadline to publish its 2025 annual accounts, citing resource demands from a €2.015 million refinancing, which temporarily reduces transparency on full-year financial performance.

Insights

Biophytis delays 2025 accounts due to refinancing workload, aiming to publish by end-May 2026.

Biophytis explains that a €2.015 million refinancing transaction occupied resources needed to complete its 2025 annual financial statements and statutory audit. Consequently, it will miss the legal April 30, 2026 publication deadline for those accounts.

Management states it is making every effort to finalize and publish the 2025 financial statements by the end of May 2026. Until those results are available, investors lack full visibility on year-end financials, and the delay itself signals some operational strain around finance and reporting processes.

Refinancing size €2.015 million Refinancing transaction cited as reason for 2025 accounts delay
Legal deadline for 2025 accounts April 30, 2026 Statutory publication deadline Biophytis confirms it will miss
Target publication timing End of May 2026 Company goal to finalize and publish 2025 financial statements
refinancing transaction financial
"Due to the €2.015 million refinancing transaction (announced in the press release..."
A refinancing transaction is when a company replaces existing debt with new borrowing to change the interest rate, payment schedule, or other loan terms—think of swapping a high-interest credit card balance for a lower-rate loan to reduce monthly costs or extend repayment time. Investors care because refinancing alters a company’s future cash payments, financial risk and flexibility; better terms can free up cash and reduce default risk, while worse terms or added borrowings can increase interest costs and pressure on profits.
statutory auditors regulatory
"finalize its closing work and its review by the statutory auditors, under appropriate conditions..."
Statutory auditors are independent, legally required professionals who examine a company's financial statements and records to confirm they are accurate and comply with law. Think of them as an impartial inspector or referee who checks the bookkeeping and internal controls; their reports give investors confidence that reported profits, losses and risks are reliable and help detect errors, fraud or accounting problems that could affect a company’s value.
clinical-stage biotechnology technical
"a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases..."
Clinical-stage biotechnology refers to biotechnology companies that are in the process of testing new medical treatments or drugs in human trials. This stage is crucial because it indicates that these treatments have shown enough promise in earlier research to be evaluated for safety and effectiveness in people. For investors, it signals a key phase where potential breakthroughs are being tested, but also involves higher risk since the outcomes are still uncertain.
forward-looking statements regulatory
"This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts..."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Phase 3 technical
"BIO101 ... is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start)..."
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

FAQ

Why is Biophytis (BPTSY) delaying its 2025 annual financial statements?
Biophytis is delaying its 2025 annual financial statements because a €2.015 million refinancing transaction required extensive discussions and negotiations. The company says this diverted internal resources from closing work and audit review, making it impossible to finalize the accounts within the original timetable.

When does Biophytis expect to publish its 2025 annual financial statements?
Biophytis states it is making every effort to finalize and publish its 2025 annual financial statements by the end of May 2026. This follows its confirmation that it will miss the original statutory publication deadline of April 30, 2026 for the 2025 fiscal-year accounts.

What role did the €2.015 million refinancing play for Biophytis (BPTSY)?
Biophytis links the delay in its 2025 annual financial statements to a €2.015 million refinancing transaction. Management reports that discussions and negotiations around this refinancing required significant attention, limiting capacity to complete closing tasks and statutory audit work on the 2025 accounts on time.

What type of company is Biophytis and where is it listed?
Biophytis is a clinical-stage biotechnology company developing drug candidates for age-related diseases, including muscular and metabolic disorders. Its ordinary shares trade on Euronext Growth Paris under ALBPS, and its American Depositary Shares are listed on the OTC market under the symbol BPTSY.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report: April 30, 2026

 

Commission File Number: 001-38974

 

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

 

 

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

x  Form 20-F ¨  Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

On April 29, 2026, Biophytis S.A. issued a press release announcing the postponement of the publication of its annual financial statements for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

 

EXHIBIT LIST

 

Exhibit   Description
99.1   Press Release dated April 29, 2026.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOPHYTIS S.A.
     
Date: April 30, 2026 By: /s/ Stanislas Veillet
    Name: Stanislas Veillet
    Title: Chairman and Chief Executive Officer

 

 

 

Exhibit 99.1

 

 

INFORMATION ON ANNUAL FINANCIAL STATEMENTS

 

Paris (France), Cambridge (Massachusetts, USA), April 29, 2026 – 11:00 p.m, CET – Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces the postponement of the publication of its annual financial statements for the year ended December 31, 2025. Due to the €2.015 million refinancing transaction (announced in the press release dated March 11, 2026), the Company had to focus its efforts on discussions and negotiations related to this refinancing.

 

Given the mobilization of its teams on the refinancing transaction, the Company considers it necessary to have additional time to finalize its closing work and its review by the statutory auditors, under appropriate conditions of quality, reliability, and compliance with applicable regulatory requirements.

 

In this context, the Company is not in a position to meet the legal deadline for the publication of the annual financial statements for the 2025 fiscal year, set for April 30, 2026. Biophytis is making every effort to finalize and publish its financial statements by the end of May 2026.

 

* * *

 

About BIOPHYTIS

 

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

 

Disclaimer

 

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company’s 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

 

Biophytis Contacts

 

Investor Relations

Investors@biophytis.com

 

Media contacts

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Nizar Berrada : nizar.berrada@taddeo.fr - +33 6 38 31 90 50

 

Page 1 sur 1

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

Keep reading

More on BPTSY

Trending in the feed

Open the live feed